Ausgabe 2/2000
Inhalt (12 Artikel)
Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
Kenneth S. Koeneman, Chinghai Kao, Song-Chu Ko, Ling Yang, Yoshitaka Wada, David F. Kallmes, Jay Y. Gillenwater, Haiyen E. Zhau, Leland W. K. Chung, Thomas A. Gardner
Transcriptionally regulated adenoviruses for prostate-specific gene therapy
Yi Lu, Mitchell S. Steiner
Adenovirus p16 gene therapy for prostate cancer
James A. Allay, Mitchell S. Steiner, Yu Zhang, Christopher P. Reed, Jody Cockroft, Yi Lu
Ad5CMVp53 gene therapy for locally advanced prostate cancer – where do we stand?
Paul Sweeney, Louis L. Pisters
Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer
Waleed Hassan, Michael A. Sanford, Savio L. C. Woo, Shu-Hsia Chen, Simon J. Hall
Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene
Moshe Shalev, Brian J. Miles, Timothy C. Thompson, Gustavo Ayala, Edward B. Butler, Estuardo Aguilar-Cordova, Dov Kadmon
Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions
Allan J. Pantuck, Amnon Zisman, Arie S. Belldegrun
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development
Linda G. Charles, Yilin C. Xie, Nicholas P. Restifo, Blake Roessler, Martin G. Sanda
Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex
David M. J. Hoffman, Robert A. Figlin
B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma
Scott J. Antonia, John D. Seigne